PMID- 22075749
OWN - NLM
STAT- MEDLINE
DCOM- 20120702
LR  - 20211021
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 59
IP  - 3
DP  - 2012 Mar
TI  - Combined aliskiren and amlodipine reduce albuminuria via reduction in renal 
      inflammation in diabetic rats.
PG  - 281-7
LID - 10.1097/FJC.0b013e31823fc3f5 [doi]
AB  - We hypothesized that compared with hydrochlorothiazide (HCTZ), the renin 
      inhibitor aliskiren (ALISK) or amlodipine (AMLO) and their combination reduce 
      albuminuria via reduction in renal inflammation, independent of blood pressure 
      (BP) changes. We studied normal and streptozotocin-induced diabetic (DM) 
      Sprague-Dawley rats treated for 6 weeks with vehicle, ALISK, HCTZ, or AMLO 
      individually and combined and evaluated the effects of treatments on BP, urine 
      albumin to creatinine ratio, renal interstitial fluid levels of angiotensin II, 
      tumor necrosis factor alpha (TNF-alpha), and interleukin 6 (IL-6) and renal 
      expression of TNF-alpha, IL-6, transforming growth factor beta 1, and nuclear factor 
      kappa B. There were no differences in BP between treatments. Only ALISK and its 
      combinations reduced renal interstitial fluid angiotensin II. Urine albumin to 
      creatinine ratio increased in DM rats and decreased with ALISK alone or combined 
      with HCTZ or AMLO. HCTZ or AMLO individually and combined did not influence urine 
      albumin to creatinine ratio. Renal interstitial fluid TNF-alpha and IL-6, and the 
      renal expression of TNF-alpha, IL-6, transforming growth factor beta 1, and nuclear 
      factor kappa B were increased in DM rats. These renal inflammatory markers were 
      reduced only with ALISK or AMLO individually or combined with other treatments. 
      We conclude that ALISK alone and combined with HCTZ or AMLO reduced albuminuria 
      in diabetes via reduction in renal inflammation, independent of BP changes.
FAU - Matavelli, Luis C
AU  - Matavelli LC
AD  - Department of Medicine, University of Virginia Health System, Charlottesville, VA 
      22908-1409, USA.
FAU - Huang, Jiqian
AU  - Huang J
FAU - Siragy, Helmy M
AU  - Siragy HM
LA  - eng
GR  - R01 HL091535/HL/NHLBI NIH HHS/United States
GR  - R01 DK078757-06/DK/NIDDK NIH HHS/United States
GR  - R01 HL091535-10/HL/NHLBI NIH HHS/United States
GR  - NIDDK-078757/PHS HHS/United States
GR  - HL091535/HL/NHLBI NIH HHS/United States
GR  - R01 DK078757/DK/NIDDK NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Amides)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Fumarates)
RN  - 0J48LPH2TH (Hydrochlorothiazide)
RN  - 1J444QC288 (Amlodipine)
RN  - 502FWN4Q32 (aliskiren)
RN  - 5W494URQ81 (Streptozocin)
RN  - EC 3.4.23.15 (Renin)
SB  - IM
MH  - Albuminuria/*drug therapy
MH  - Amides/administration & dosage/*pharmacology
MH  - Amlodipine/administration & dosage/*pharmacology
MH  - Animals
MH  - Antihypertensive Agents/administration & dosage/pharmacology
MH  - Blood Pressure/drug effects
MH  - Diabetes Mellitus, Experimental/drug therapy/physiopathology
MH  - Drug Therapy, Combination
MH  - Fumarates/administration & dosage/*pharmacology
MH  - Hydrochlorothiazide/administration & dosage/*pharmacology
MH  - Inflammation/drug therapy/physiopathology
MH  - Kidney
MH  - Male
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Renin/antagonists & inhibitors
MH  - Streptozocin
PMC - PMC3296909
MID - NIHMS341977
EDAT- 2011/11/15 06:00
MHDA- 2012/07/03 06:00
PMCR- 2013/03/01
CRDT- 2011/11/15 06:00
PHST- 2011/11/15 06:00 [entrez]
PHST- 2011/11/15 06:00 [pubmed]
PHST- 2012/07/03 06:00 [medline]
PHST- 2013/03/01 00:00 [pmc-release]
AID - 10.1097/FJC.0b013e31823fc3f5 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2012 Mar;59(3):281-7. doi: 10.1097/FJC.0b013e31823fc3f5.